Extract

Infigratinib phosphate is an antineoplastic agent.

Class: 10:00 • Antineoplastic Agents (AHFS primary)

Brands: Truseltiq®

Uses

Infigratinib phosphate has the following uses:

...

Dosage and Administration

General

Infigratinib phosphate is available in the following dosage form(s) and strength(s): Capsules: 25 mg and 100 mg; provided in 50-, 75-, 100-, and 125-mg dose packs.

Dosage

It isessentialthat the manufacturer’s labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary:

Adults

Dosage and Administration

...

Cautions

Contraindications

None.

Warnings/Precautions

Ocular Toxicity

Retinal Pigment Epithelial Detachment (RPED)

Infigratinib phosphate can cause RPED, which may cause symptoms such as blurred vision.

Among 351 patients who received infigratinib phosphate across clinical trials where ophthalmologic monitoring did not routinely include optical coherence tomography (OCT), RPED occurred in 11% of patients, including patients with asymptomatic RPED. The median time to first onset of RPED was 26 days. RPED led to dose interruption/reduction of infigratinib phosphate in 3.4% of patients, and permanent discontinuation in 0.6% of patients.

You do not currently have access to this article.

Comments

0 Comments
Submit a comment
You have entered an invalid code
Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email.